Clinical study of alpha-GalactosylCeramide-pulsed dendritic cells in patients with advanced and recurrent lung cancer
Phase 1
- Conditions
- primary lung cancer
- Registration Number
- JPRN-UMIN000000948
- Lead Sponsor
- Department of Thoracic Surgery, Graduate School of Medicine, Chiba University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 23
Inclusion Criteria
Not provided
Exclusion Criteria
the presence of active infection; a history of hepatitis; a positive response for hepatitis B surface antigen, or human immunodeficiency virus (HIV), hepatitis C virus, or human T-lymphotrophic virus antibodies; evedence for other malignant diseases; serious cardiac disease, recieived concurrent corticosteroid therapy; pregnancy or lactation; been judged to be inappropriate to participate in this study by principle investigator or co-investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety
- Secondary Outcome Measures
Name Time Method Immunological response and Clinical response
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the mechanism of alpha-GalactosylCeramide-pulsed dendritic cells in activating NKT cells for lung cancer immunotherapy?
How does alpha-GalCer dendritic cell therapy compare to standard-of-care immunotherapies like PD-1 inhibitors in advanced lung cancer?
Which biomarkers predict response to alpha-GalactosylCeramide-pulsed dendritic cell therapy in lung cancer patients?
What adverse events were observed in the phase I trial JPRN-UMIN000000948 using alpha-GalCer dendritic cells and their management strategies?
Are there other NKT cell agonists or combination therapies with alpha-GalCer that enhance lung cancer treatment efficacy in phase I trials?